Mitchell Center for Alzheimer's Disease and Related Brain Disorders, Department of Neurology, University of Texas Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA.
Neurology Unit, Università di Milano, Centro Dino Ferrari, Fondazione Ca' Granda, IRCC Ospedale Policlinico, via F. Sforza 35, 20122 Milan, Italy.
Cell Rep. 2014 Apr 10;7(1):261-8. doi: 10.1016/j.celrep.2014.02.031. Epub 2014 Mar 20.
Alzheimer's disease (AD) diagnosis is hampered by the lack of early, sensitive, and objective laboratory tests. We describe a sensitive method for biochemical diagnosis of AD based on specific detection of misfolded Aβ oligomers, which play a central role in AD pathogenesis. The protein misfolding cyclic amplification assay (Aβ-PMCA), exploits the functional property of Aβ oligomers to seed the polymerization of monomeric Aβ. Aβ-PMCA allowed detection of as little as 3 fmol of Aβ oligomers. Most importantly, using cerebrospinal fluid, we were able to distinguish AD patients from control individuals affected by a variety of other neurodegenerative disorders or nondegenerative neurological diseases with overall sensitivity of 90% and specificity of 92%. These findings provide the proof-of-principle basis for developing a highly sensitive and specific biochemical test for AD diagnosis.
阿尔茨海默病(AD)的诊断受到缺乏早期、敏感和客观的实验室检测方法的阻碍。我们描述了一种基于对异常折叠的 Aβ寡聚体的特异性检测的 AD 生化诊断的敏感方法,该寡聚体在 AD 的发病机制中起核心作用。蛋白错误折叠循环扩增检测(Aβ-PMCA)利用 Aβ寡聚体的功能特性来引发单体 Aβ的聚合。Aβ-PMCA 可以检测到低至 3 fmol 的 Aβ寡聚体。最重要的是,我们使用脑脊液能够将 AD 患者与受各种其他神经退行性疾病或非神经退行性神经系统疾病影响的对照组个体区分开来,总灵敏度为 90%,特异性为 92%。这些发现为开发用于 AD 诊断的高度敏感和特异的生化检测方法提供了原理验证基础。